Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766902 | 0.84 | ERN1 (0.62) | ERN1TDP1 | |
| SCHEMBL18909533 | 0.81 | ERN1 (0.55) | ERN1PTPRF | |
| SCHEMBL15592039 | 0.79 | ERN1 (0.55) | ERN1 | |
| SCHEMBL13018140 | 0.76 | ERN1 (0.61) | ERN1NPC1 | |
| SCHEMBL28136933 | 0.74 | PTPRC (0.46) | NPC1 | |
| SCHEMBL2590571 | 0.73 | MGAM (0.42) | ERN1PIK3CD | |
| SCHEMBL12766900 | 0.72 | ERN1 (1.00) | ERN1NPC1 | |
| SCHEMBL12766888 | 0.70 | ERN1 (0.73) | ERN1PTPRFNPC1 | |
| SCHEMBL13278316 | 0.69 | PIK3CD (0.35) | ERN1PIK3CDHTR6 | |
| SCHEMBL18717000 | 0.69 | ERN1 (0.52) | ERN1PTPRFNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885PIK3CD 3340/4885HTR6 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.